Tapering vs. Cold Turkey: How Physicians Actually Discontinue GLP-1 Therapy in 2026

Unlike benzodiazepines or SSRIs, GLP-1 receptor agonists have no withdrawal syndrome in the classical sense. Stopping abruptly is not dangerous. So why do most physicians now recommend a taper anyway? The answer is behavioral, not pharmacological.

Why Taper a Drug With No Withdrawal?

When a patient on 2.4mg semaglutide stops outright, full appetite returns over about a month against habits that were built with pharmacological assistance. When the same patient steps down to 1.7mg, then 1.0mg, then 0.5mg over several months, appetite returns incrementally — and each increment is a manageable behavioral test. Physicians describe it as "letting the patient catch the weight of the appetite a little at a time."

The Two Common Taper Structures

1. Dose step-down

Reverse the titration schedule: drop one dose tier every 4–8 weeks, holding longer at any tier where hunger feels unmanageable or weight begins climbing. Total taper time: 3–6 months from a full maintenance dose.

2. Interval stretching

Keep the same dose but extend the interval — weekly to every 10 days, then every 14. Because steady-state levels fall as intervals lengthen, this is functionally a taper. Some patients find it simpler than tracking changing doses, and on flat-priced plans it also stretches each vial further.

Who Should Not Stop Abruptly

Patients using GLP-1s for type 2 diabetes are a genuinely different category. Discontinuation removes glycemic control, and A1C can deteriorate within weeks. These patients need a replacement glycemic plan — whether metformin optimization, another agent, or intensive monitoring — coordinated before the last dose. If your prescriber shrugs at this question, that's a red flag about the quality of your care.

The Maintenance-Dose Alternative

A growing middle path in 2026: rather than discontinuing, patients drop to a low maintenance dose (0.5–1.0mg semaglutide equivalents) indefinitely. Early evidence and widespread clinical experience suggest many patients hold their weight at doses well below what was needed to lose it. With flat-price providers, the economics of staying on a low dose have become trivial:

The Bottom Line

Cold turkey is safe but behaviorally abrupt; tapering is gentler and gives you feedback at each step. Either way, the decision deserves a plan: a step schedule, a monitoring cadence, and a pre-agreed restart criterion. Discontinuation done well looks a lot like initiation done well — deliberate, monitored, and reversible.